Acquisitions vs FDA Actions
Side-by-side coverage analysis for Acquisitions and FDA Actions.
This comparison applies the same classification pipeline used across every story on this site, which scores each linked entity at a minimum 35 percent relevance threshold before it is surfaced. According to our editorial methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
Acquisitions
M&A activity
- Stories
- 21
- Avg Impact
- 6.7/10
- Dominant Tone
- Positive
- Latest
- 4d ago
FDA Actions
Approvals, rejections, priority reviews
- Stories
- 73
- Avg Impact
- 6.6/10
- Dominant Tone
- Positive
- Latest
- 2d ago
Recent Headlines
Acquisitions
- Novartis India's 5 therapy-area acquisition plan targets Tier 2/3 growth
- Clearmind Medicine to Acquire 51% of Charging Robotics Startup
- Biotech Pivot: Aspire Snaps Up Auto Supplier with $200M Revenue for $30M Cash
- AstraZeneca, BMS Eye $400B Union to Build Cancer Powerhouse
- Viking's $190B Obesity Pipeline Beckons: Could It Be the Next $10B Biotech Buyout?
- SNDL Secures 69.4% Debt Control via Parallel Foreclosure, Prepares Pharma-Style Consolidation
- 23andMe's $46.75M data breach toll and the genetic testing trust deficit
- Samsung Biologics Expands Peptide CDMO Power with $1.46B PolyPeptide Deal
- Cancer diagnostics push Abbott's 2026 EPS guidance to $5.45-$5.60
- Partnered Health breach puts patient data at risk amid Bupa takeover
FDA Actions
- 3 in 5 abortions use mifepristone as 5th Circuit weighs limits
- FDA Drug Chief to Oversee 3 Psychedelic Candidates: Psilocybin, MDMA, LSD
- FDA Names 4 Center Directors as Psychedelics Reviews Take Shape
- Mifepristone in 60% of U.S. abortions faces FDA rule fight in 5th Circuit
- Endometriosis tests advance abroad while U.S. lags for 1 in 10 women
- Rasonque Approved: KRAS Inhibitor Doubles Survival to 13.2 Months
- ICP DAS-BMP TPU with 20-40% Barium Sulfate Targets Implantable Devices
- Druckenmiller's Q2 RYTM Bet Targets 2 FDA Nods in Rare Obesity
- Zeon's FDA FSMA + NSF 21 CFR Part 111 cGMP Boost India CDMO Credibility
- Opdivo's 1/12th Dose Shows Efficacy in Indian Study, Sparking FDA Label Debate